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ABSTRACT - Introduction - Type 2 diabetes is a metabolic disease characterized by 
chronic hyperglycemia associated with several organs damage and failure. It is 
the most common cause of blindness, amputation and kidney failure in western 
adults, besides increase the risk of coronary disease and stroke with high mortality 
of patients. The association of type 2 diabetes with obesity is really significant. 
Obese diabetic patients had a better glucose control after bariatric surgery even 
prior to weight loss. Methods - A systematic review in Pubmed, Bireme and 
Scielo research sites was made, using “Diabetes Mellitus”, “Bariatric Surgery” and 
“Obesity” keywords. Were selected the studies related to surgical techniques in the 
treatment of obesity and type 2 diabetes. The papers presented at the 1st and 2nd 
World Congress of Interventional Therapies for Type 2 Diabetes was also included. 
Conclusion - Surgical treatment of patients with obesity and type 2 diabetes 
showed important initial results controling blood glucose. However, the procedures 
and techniques used must be more investigated in randomized controlled trials 
comparing the clinical and surgical treatments, in  animals and in humans.
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RESUMO - Introdução - O diabete melito tipo 2 é doença metabólica caracterizada 
por hiperglicemia crônica que está associada com dano e insuficiência de vários 
órgãos. A evolução da doença é a causa mais comum de cegueira, amputações 
e insuficiência renal em adultos no ocidente, além de aumentar a incidência de 
infarto agudo do miocárdio e acidente vascular cerebral, com maior mortalidade 
dos pacientes. A associação dele com obesidade é relevante. Os pacientes obesos 
diabéticos quando submetidos ao tratamento cirúrgico da obesidade apresentam 
melhor controle da glicemia, mesmo antes de perderem peso. Método - Foi 
realizada revisão de literatura nos sites de pesquisa PubMed, Bireme e Scielo, com 
os descritores “Diabetes Mellitus”, “Cirurgia Bariátrica” e “Obesidade”. Selecionaram-
se, principalmente, os estudos de aplicação de  técnicas cirúrgicas nos tratamentos 
da obesidade e do diabete tipo 2. Adicionalmente foram revisados os trabalhos 
apresentados no 1st e 2nd World Congress of Interventional Therapies for Type 2 
Diabetes. Conclusão - O tratamento cirúrgico de pacientes obesos e diabéticos tipo 
2 tem mostrado bom resultado inicial, com controle clínico precoce da glicemia. 
Porém, os procedimentos e técnicas empregados devem ser melhor investigados 
em  estudos randomizados e controlados, comparando os tratamentos cirúrgico e 
clinico, em  animais de experimentação e em seres  humanos.
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INTRODUCTION 
Diabetes mellitus type 2 (DM2) is a metabolic disorder characterized by hyperglycemia triggered by deficient secretion of insulin from pancreatic β cells and/or increased peripheral resistance to its 
action. The chronic hyperglycemia is associated with damage and failure 
of various organs. The disease is the most common cause of blindness, 
amputation and kidney failure in adults in the West and as a coronary risk 
factor, increases the incidence of myocardial infarction and stroke1.
The prevalence of the disease has been growing in scale. It is estimated 
that approximately 150 million people worldwide suffer from DM2, 
increasing to approximately 300 million in 2025, with the emergence of a 
new case every five seconds14.
In Brazil, the eighth largest number of cases, the disease affected 4.5 
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million Brazilians in 2000, with the perspective of twice 
that number by 2030, according to the World Health 
Organization30.
The association between obesity and diabetes is 
well defined. Mainly located in the abdominal region 
may increase the risk by 10 times, and for each 10% 
increase in body weight, thre is an increase of 2 mg/dL 
in fasting plasma glucose15.
According to the World Health Organization31, 
obesity increases morbidity and mortality related 
to cardiovascular disease, insulin resistance, DM2, 
dyslipidemia, sleep apnea, orthopedic problems, lung 
diseases and psychological disorders. As far as, losing 
weight contributes greatly to the success of therapy in 
diabetic patients, the fight against obesity has gained 
increasing importance. 
METHOD
Literature review was conducted on sites search 
PubMed, BIREME, SciELO, with the headings “Diabetes 
Mellitus”, “Bariatric Surgery” and “Obesity”. Were 
selected mainly studies with application on surgical 
techniques in the treatment of obesity and DM2. In 
addition was reviewed the papers presented at the 
1st and 2nd World Congress of Interventional Therapies 
for Type 2 Diabetes held in New York in 2008 and 
2011, respectively. 
Observations obtained with surgical treatment
Patients with severe obesity, ie BMI greater 
than or equal to 40 kg/m2, are at increased risk of 
comorbidities28. For these individuals, as well as those 
with a BMI equal to or greater than 35 and who already 
had associated diseases, bariatric surgery has proven 
effective in improving these diseases, including DM2.
The first bariatric operations began in the 50s 
and were disabsortive, decreasing the size of the small 
intestine to approximately 50 cm. These techniques 
led to diarrhea, excessive weight loss (60% to 70%) 
and severe malnutrition.
Friedman et al.12 described improvement in 
diabetes mellitus after the completion of subtotal 
gastrectomy for peptic ulcer disease, demonstrating 
the influence of digestive operations in non-obese.
Cummings and Overduin8 studies in 2007 
demonstrated the action of intestinal peptides, called 
incretins, peripheral and centrally acting on glycemic 
control and regulation of food intake. They suggested 
that the change in anatomy and physiology, provided 
by the operation, influence their action. Currently, the 
researches are focused on enteroinsular axis of GLP-1, 
GIP, PYY, ghrelin and gastrin.
Glucagon-like peptide-1 (GLP-1) is shown in 
the central nervous system and in L cells of the small 
intestine and secreted after eating in proportion to 
the caloric intake, especially when the food reaches 
the most distal portions of the intestine. Rask et 
al.20 evaluated the effect of GLP-1 in satiety and its 
influence on  body weight in the long- term. Evidence 
suggests that the secretion and response to food 
stimulation of GLP-1 are reduced in obese and weight 
loss normalizes these levels. Besides the role in control 
of hunger, GLP-1 also increases insulin secretion 
by stimulating the expression of the insulin gene 
and enhance every step of their biosynthesis. The 
glucose-dependent insulinotropic polypeptide (GIP) 
is synthesized and secreted in the duodenum and 
proximal jejunum, mainly in response to glucose 
and fat, and influence the synthesis and secretion 
of insulin. Rubino et al.24 observed reduction of GIP 
after bariatric surgery in obese patients, but not in the 
group obese nondiabetic; they identified gaps in the 
response of GIP on the degree of insulin resistance, 
suggesting that the state of insulin resistance is 
associated with a defect in the response to GIP. These 
authors also demonstrated that PYY participates in 
the mechanism of appetite and weight control. It 
is a counterpart to the incretin GLP1 produced in L 
cells of the digestive tract, along its entire length, 
being a polypeptide similar to GLP-1. Its production 
is stimulated by intraluminal nutrients, modulate and 
inhibit several functions of the gastrointestinal tract, 
including the pancreas, especially insulin.
Cummings et al.8 says that gastrin is a unique 
orexigenic hormone produced primarily by the 
stomach and proximal small intestine, regulating 
appetite in several species. Increases gastrointestinal 
motility and decreases insulin secretion by action on 
receptors in the pancreatic islets. Circulates shortly 
before meals and is suppressed by nutrient intake, 
mainly carbohydrates.The secretion of preprandial 
ghrelin seems to be a response mediated by the 
sympathetic nervous system. Has a role in controlling 
food and body weight regulation by direct influence 
on the control of hunger; its levels are inversely 
proportional to body weight. Weight loss increases it.
Bariatric surgery interferes with the enteroinsular 
mechanism positively influencing the production of 
these and other hormones that somehow work in 
promoting pancreatic β cell insulin production21. 
Surgical techniques
Considering the mechanism that induces 
weight loss, surgical procedures are often classified 
as restrictive or disabsorptive. However, knowledge 
of other mechanisms, such as the action of incretins 
in the outcome of surgical procedures, makes this 
classification questioned because not only the 
restriction or malabsorption leads to weight control. 
Restrictive operations
These procedures aim to reduce the gastric 
cavity. Examples are the adjustable gastric band and 
sleeve gastrectomy (sleeve). These procedures do not 
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involve exclusion of the intestinal tract.
The adjustable gastric band (Figure 1) developed 
in 1982 in Austria, had greater popularity with the 
diffusion of laparoscopic surgery of the 90’s, with 
the adjustable system being applied in the surgical 
treatment of obesity.
Dixon et al.10 observed significant improvement 
of diabetes in patients undergoing adjustable gastric 
band with a BMI between 30 and 40 in follow-up 
period of two years. The author observed remission 
in 73% of cases compared to 13% in a group that 
underwent clinical treatment. This operation has a 
restrictive and not metabolic effect. The success with 
respect to weight loss and control of diseases is not as 
effective when compared to other techniques3,4. Due 
to high rates of weight regained, many surgeons have 
sought other alternatives31. 
The vertical gastrectomy (sleeve) is one of the 
new procedures that have been accepted worldwide 
(Figure 2). In it, the surgeon performs up to 80% 
removal of the stomach, leaving a vertical cavity. 
Besides being restrictive procedure takes action to 
reduce ghrelin. Initially it was first proposed as a two-
step procedure, associated in a second time to one 
malabsorptive procedure for patients at high surgical 
risk. In addition to the restrictive effect, authors 
have suggested an incretin effect increasing gastric 
emptying which could lead to more effective release 
of GLP-1, showing similar results when compared with 
malabsorptive procedures2. 
Disabsortive operations 
Gastroplasty with gastrointestinal Roux-en-Y 
bypass (RYGB) (Figure 3) is the most commonly 
performed bariatric surgical procedure in the world 
and is considered the “gold standard” treatment for 
morbid obesity. In this operation, most of the stomach, 
duodenum and proximal jejunum are no longer part 
of the circuit passage of food, reducing the length of 
the path of common limb to food and biliopancreatic 
juice to about 450 cm5.
Pories18  has published a paper describing 
the effects of surgical treatment by RYGB. This 
study included 515 morbidly obese patients and 
that 288 (55.95%) were diabetic or had glucose 
intolerance. They were assessed preoperatively weekly 
during the first month and monthly until the sixth 
month postoperatively. After surgery only 30 (5.8%) 
patients remained diabetic. Patients that did not 
normalize glucose levels after surgery had diabetes 
during a longer time than those who improved in the 
postoperative evaluations.
These data have been reproduced in several 
studies and meta-analysis3,4.
Schauer et al.27 studied obese DM2 patients 
undergoing RYGB. The assessment of diabetes control 
was performed with the fasting plasma glucose and 
HbA1c dosage, as well as evaluating the need for 
medication. They achieved a reduction in fasting 
plasma glucose and glycosylated hemoglobin in 
83%, reduction of oral medication in 80%, and 79% 
in insulin. Patients with shorter disease duration (<5 
years) and with great weight loss showed complete 
resolution of diabetes.    
The concept of biliopancreatic diversion (BPD) 
(Figure 4) was first described by Nicola Scopinaro of 
Genova, Italy in 1979. It consists of operation with 
greater restriction and malabsorption effect and 
leads to significant greater weight loss compared 
to RYGB, but can cause complications such as protein 
malnutrition, hypocalcemia, bone demineralization, 
diarrhea, gastric ulcer, iron deficiency, vitamin B12 
and fat soluble vitamins and excessive flatulence. The 
author working with 312 patients and 10 years of 
follow-up had 97% resolution of diabetes (26,27). Other 
Fonte: (http://www.sbcbm.org.br/pacientes_duvidas_frequentes.php)
FIGURE 1 - Adjustable gastric band
Fonte:  (http://www.ifso.com/index.aspx?id=SleeveGastrectomy1)
FIGURE 2 - Vertical gastrectomy
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authors have added some modifications in the original 
technique with good results31. 
Another operation on the same principles, is the 
one proposed by Hess and Hess and Marceau, variant 
of “duodenal switch” (Figure 5). It is a vertical 
gastrectomy and differs from Scopinaro operation by 
keeping the pylorus. This would maintain the benefits 
of  biliopancretic bypass in weight loss and control of 
comorbidities, decreasing some complications such as 
dumping and marginal ulcer13. 
The control of diabetes would not be a secondary 
response to the treatment of obesity, but the exclusion 
of duodenojejunal segment. This idea is corroborated 
by several studies that show the improvement of 
diabetes a few days after surgery in obese and also 
the resolution of it in non-obese patients underwent 
duodenojejunal bypass, not associated with gastric 
restrictive operation16.
The procedures (RYGB and BPD) include the 
diversion of part of the duodenum and jejunum. Peptides 
are released in this part of the digestive tract, 
functioning in the regulation of pancreatic beta 
cells that produce insulin in physiological state, and 
in diabetes. Enteroinsular changes induced by the 
operation may explain the anti-diabetogenic effect 
of the procedure. Thus, the improvement of diabetes 
would not effect the treatment of obesity, but rather a 
direct effect on duodenojejunal exclusion, and it can 
be achieved in individuals without obesity. To test this 
hypothesis Rubino and Marescaux24 studied the effect 
of duodenojejunal bypass in Goto-Kakizaki rats (GK) 
- most widely used model for studying diabetes in 
animals without obesity. The operation has kept intact 
the volume of the stomach, with maintenance of caloric 
intake and weight maintenance of the animals. The 
result of this study was the change of severe diabetes, 
independently from dietary changes and weight of 
animals. The authors concluded that this procedure 
should be implemented in humans with diabetes 
to reverse the disease, without causing potential 
nutritional damage, common in bariatric procedures, 
such as vitamin deficiency and iron deficiency anemia.
This procedure was performed clinically 
by Cohen et al.6, resulting in euglycemia and reduction 
of glycosylated hemoglobin to normal levels, evident 
even before hospital discharge in some cases.
De Paula et al.9 evaluated the applicability 
of a technique that consists in performing sleeve 
gastrectomy and ileal interposition in the proximal 
jejunum. The physiological explanation is based 
on early contact of food with the distal ileum with 
Fonte: (http://www.sbcbm.org.br/pacientes_duvidas_frequentes.php)
FIGURE 3 - Gastroplasty with gastrointestinal bypass Roux-
en-Y
Fonte: (http://www.ifso.com/index.aspx?id=bpd)
FIGURE 4 - Biliopancreatic diversion (Scopinaro)
Fonte:(http://www.sbcbm.org.br/pacientes_duvidas_frequentes.php)
FIGURE 5 - Duodenal switch
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consequent earlier release of incretin. In analysis of 
21 patients who underwent this operation with an 
average BMI of 39.2 kg/m² and median follow-up of 11 
months, resulted in weight loss of 42.4% in 16 months 
and an average BMI of  23.1 kg/m². In an assessment 
of six months all patients with DM2 and sleep apnea 
were cured.
Despite these arguments to defend the use of 
surgery in the treatment of diabetes, this concept 
inevitably suffers resistance from experts who 
consider the disease as a clinical treatment. They 
use the argument of higher morbimortality with the 
procedure, despite knowing that diabetes is associated 
with severe clinical complications, reduction of life 
expectancy and quality of life.
The control of diabetes by operations was 
initially thought to occur due by weight control; 
however, the rapid improvement of diabetes 
even before significant weight loss have shown 
different ways of action. Papers by Rubino21 and 
Scopinaro26 showed that the improvement of diabetes 
usually occurs in the first week after surgery and the 
patients who underwent the Scopinaro biliopancreatic 
diversion or duodenal switch were those with the 
highest rates of improvement with normal diet, 
including carbohydrates. The normalization of blood 
glucose occurs in the early postoperative period, 
even before a significant weight loss to explain this 
improvement18. This suggests that the anatomical and 
functional changes caused by the operation are the 
factors that contributed most to the improvement and, 
in most cases, normalization of parameters related to 
metabolic syndrome.
Two theories have been proposed to explain the 
beneficial effect of DJB (and RYGB and BPD) in DM2. One 
claims to be the result of disease control the discharge of 
nutrients from the chyme directly in the distal intestine, 
increasing the release of incretin and GLP-1. Another is 
based on the exclusion of the duodenum and proximal 
jejunum from food transit, possibly preventing the 
secretion of a specific signal that promotes insulin 
resistance and DM2. This second theory was proven in 
animals and subsequently in humans21,24.
In meta-analysis, Buchwald et al.3,4 included 
bariatric surgery studies published from January 1990 
until April 2006. Were reviewed the cases of patients in 
whom there was resolution of clinical manifestations 
and improvement in short-term (<2 years after bariatric 
surgery) and long-term, based on metabolic data of 
insulin levels, glycosylated  hemoglobin (HbA1c) and 
fasting glucose levels. In the 621 studies included in 
this systematic review, 78% of diabetic patients had 
resolution of clinical manifestations of DM2, and 
about 86.6% improved. The resolution was greater 
for patients undergoing BPD (95.1%), followed by the 
subject to RYGB (80.3%) and after adjustable gastric 
banding (56.7%). The proportion of patients with 
resolution or improvement of diabetes was similar in 
both, short (<2 years) and long-term (> 2 years).
Laferrere et al.14 compared a group of obese 
DM2 patients undergoing RYGB (n = 9) with another 
(n = 10)  in which was offered low-calorie diet and 
drugs for treatment of diabetes. The first was analyzed 
before and one month after the procedure, and 
medical therapy before and after loss of 10 kg. Besides 
the analysis of glucose, insulin, proinsulin, glucagon 
levels were measured GLP-1 and GIP, fasting and after 
stimulation with glucose. GLP-1 after oral glucose 
increased six times, the effect of incretins increased 
fivefold after RYGB, but not following the diet, the level 
of postprandial glucose also decreased more after 
the operation. In addition to the improved quality of 
life of patients undergoing bariatric surgery17, it was 
observed that diabetics have an clinical improvement 
before a large weight loss. This has opened avenues 
for research of several factors as responsible for the 
return to euglycemia and reduction of medications in 
80% to 100% of these patients11. But there is no data 
on the impact on chronic micro and macrovascular 
complications; therefore, there are doubts if will 
happen an increase on longevity of patients. 
Patients with DM2 can be operated regardless of 
their BMI?
Besides the difficulty with diabetic control with 
lower obesity or only overweight and racial differences, 
studies are looking for scientific based criteria for 
surgical indication in these situations, nowadays well 
defined for obese grade 2 and 3.
Diabetes Surgery Summit held in April 2007 in 
Rome, set the criteria for use of this form of treatment in 
DM2. Obese patients (BMI ≥ 30 kg/m2) are candidates 
for surgical treatment with duodenojejunal bypass 
with or without a gastric restrictive procedure. Was 
approved by consensus the use of RYGB as a technique 
of choice21.
Considering the evidence that most patients 
who underwent RYGB or BPD remains in remission of 
diabetes without the need for medication on several 
years of monitoring, there is a definite reason for 
operation. Clinical experience with bariatric surgery 
and data from investigations in animals suggest now 
that the operation in patients with DM2 should not 
be based on current BMI of 35 kg/m2, but on the 
assessment of risk/benefit, often faced by individuals 
with BMI less than 35 with diabetes and other 
comorbidities that affect quality of life. There is need 
to set other parameters to define the ideal candidate 
and the most appropriate type of operation. This was 
observed in the study of de Sa et al.28 where 27 patients 
with uncontrolled DM2 who underwent RYGB with 
observation of 20 months, found complete resolution 
of diabetes, blood glucose below 100 mg/dL and 
glycosylated hemoglobin below 6%; in postoperative 
evaluation 100% glucose and 48% resolution of 
diabetes was found. 




The procedures and results of operations to treat 
DM2 need to be better evaluated in further randomized 
controlled trials comparing surgical treatment with 
medical therapy. Only then, in the future, there may 
be better conclusions that can establish the best care 
that should be offered to patients with the possibility 
of permanent cure of the disease.
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